



## MICRO-INVASIVE TECHNOLOGY INC.

**MITI Newsletter, Vol.1, No. 3**

**November, 2006**

These last few months have been an extremely exciting time for MITI.

We have continued to make great progress in testing the effectiveness of our therapeutic light technology. In addition to working with Ethide and MicroTest Laboratories, we are now collaborating with Dr. Barry Kreiswirth, an internationally recognized pioneer in Molecular Epidemiology, and his team at the Public Health Institute at Rutgers University. They have conducted tests of our technology's ability to kill antibiotic-resistant bacteria such as *MRSA 300*, the major cause of hospital-bred infections with lightwaves. The initial test results are excellent.

Dr. Kreiswirth is a Principal Investigator of the Institute, a Professor of Medicine at the Rutgers School of Medicine, and author of numerous papers on antibiotic-resistant bacteria. He and his team have done crucial work in characterizing community-onset methicillin-resistant *S. aureus* strains from both prevalence studies and incidence cases.

We are also pleased to announce that Dr. Robert Moellering will be advising us. Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research and the Herman Ludwig Blumgart Professor of Medicine at Harvard, and the Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel-Deaconess Medical Center in Boston. He is a global expert on infectious diseases and is very interested in our demonstrated ability to kill antibiotic-resistant bacteria.

The Company has been invited to give a paper on our groundbreaking lightwave technology at the SPIE BIOS 2007 Conference in San Jose this coming January. This is an International Biomedical Optical Symposium, and it is a great honor to be asked to present a technical paper. And, we are planning to return to the SAGES (Society of American Gastrointestinal Endoscopic Surgeons) Conference in the spring.

The design and construction of our new 10mm disposable lightguide endoscope is now complete, and we are currently preparing the necessary documentation required for FDA approval. Once FDA approval is received, we will begin commercialization and production on the 10 millimeter scope, our digital camera system is already listed.

In October, we submitted proposals to the National Institutes of Health for a Therapeutic Nasal Endoscope and a Topographical Light Disinfectant System. Additional proposals dealing with Antimicrobial Lightwave Therapy and its patented ability to kill antibiotic-resistant super-bacteria will be filed by the end of this month. Patent applications are also being filed on all of these new technological developments.

We have also made significant progress on our other products including; a 5mm version of our disposable light guide endoscope, and a flexible "chip-on-a-stick" disposable Gastro/Colonoscopy and laparoscope. A request for a Federal Small Business Innovative

Research Grant to aid this effort will be filed in December.

Your Board of Directors has developed an action plan that targets our resources to bring the 10mm endoscope to market; to continue evaluation of the therapeutic light technology; and to continue to seek institutional investors. Chuck Dettman has stepped up to become our new Chairman of the Board; this will free John Bala to devote his time exclusively to readying our upcoming product line for market.

Our new website at [www.miticorp.com](http://www.miticorp.com) has been up and running since late July; we invite you all to visit it, and would appreciate your feedback as to how it can be improved.

None of these developments would have occurred without your support, they would be only "good ideas." Our new offices in Danielson, CT enable us to continue development of cutting edge imaging and therapeutic endoscopes for the next generation of minimally invasive surgical tools.

Our mission is to provide minimally invasive imaging and therapeutic

endoscopic technology and products that are easier and safer for surgeons to use; to reduce patient trauma and improve clinical outcomes; and to concurrently reduce healthcare costs.

Our endoscopic products will offer higher quality images, reduced operating room workload, and increased reliability over current instruments at a significantly lower cost. We will continue design and development of disposable and non-disposable, rigid and flexible endoscopes and systems. And, as you know, our proprietary therapeutic technology can destroy bacteria that cause antibiotic-resistant infection, and can provide fluorescent and infrared imagery and direct laser intervention through an endoscope.

MITI holds two issued U.S. patents and eight pending patent applications related to its technology. The issued patents cover core pulsed lightwave therapy and the concept of interactive digital imaging. The pending applications cover the **DirectView** and **TheraScope** endoscopes, new optical imaging elements, and video imaging with the use of pulsed ultraviolet and infrared light.

**MITI OFFICES**  
**934 N. Main Street**  
**Danielson, CT 06239**

